Ryuji Nakamura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ryuji Nakamura has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Hirobumi Oikawa
Department of Radiation Oncology, Iwate Medical University, Morioka, Japan
3 shared publicationsShigeru Ehara
3 shared publicationsAki Yoshida
Department of Radiology Iwate Medical University 19-1 Uchimaru 020-8505 Morioka Iwate Japan
1 shared publicationHiromichi Ishiyama
1 shared publicationHisanori Ariga
Department of Radiation Oncology, Iwate Medical University, Morioka, Japan
1 shared publication- Hisanori Ariga
Department of Radiology, Iwate Medical University School of Medicine, Uchimaru 19-1, Morioka, 020-8505, Japan
1 shared publication
Latest Publications
- 30 July 2018
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 38 (8) , 4827-4831
Partial Bladder Boost Using Lipiodol Marking During Image-guided Radiotherapy for Bladder Cancer
Background/Aim: Secure dose escalation is required to compensate avoidance of concurrent chemotherapy in radiotherapy for increasing elderly bladder cancer. We aimed to evaluate the efficacy of lipiodol submucosally injected as a fiducial marker during image-guided radiotherapy (Lip-IGRT) for muscle invasive bladder cancer (BC). Patients and Methods: Twenty-three patients with T2a-4aN0-1M0 BC underwent whole-bladder irradiation of 46 Gy and Lip-IGRT of 20 Gy, conventionally. The bladder volume exposed to 19 Gy (bV19:%) on Lip-IGRT was referred as an index predicting cystitis. Results: Lipiodol consistently highlighted the boundaries of 20 tumors (88%) on planning and portal verification images. Three of 4 patients under oral anticoagulant agents usage were complicated with grade ≥2 hematuria for 3 days (a patient with a bV19 of >50%) or more than a year (2 patients with bV19 of <50%) after the injection. The 3-year overall survival and disease-free survival rates were 70.4% and 71.1%, respectively. Conclusion: Lipiodol marking is an effective way of demarcating BC. However, it is necessary to address the comorbidities of elderly patients.
- 30 July 2018
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 38 (8) , 4827-4831
Partial Bladder Boost Using Lipiodol Marking During Image-guided Radiotherapy for Bladder Cancer
Background/Aim: Secure dose escalation is required to compensate avoidance of concurrent chemotherapy in radiotherapy for increasing elderly bladder cancer. We aimed to evaluate the efficacy of lipiodol submucosally injected as a fiducial marker during image-guided radiotherapy (Lip-IGRT) for muscle invasive bladder cancer (BC). Patients and Methods: Twenty-three patients with T2a-4aN0-1M0 BC underwent whole-bladder irradiation of 46 Gy and Lip-IGRT of 20 Gy, conventionally. The bladder volume exposed to 19 Gy (bV19:%) on Lip-IGRT was referred as an index predicting cystitis. Results: Lipiodol consistently highlighted the boundaries of 20 tumors (88%) on planning and portal verification images. Three of 4 patients under oral anticoagulant agents usage were complicated with grade ≥2 hematuria for 3 days (a patient with a bV19 of >50%) or more than a year (2 patients with bV19 of <50%) after the injection. The 3-year overall survival and disease-free survival rates were 70.4% and 71.1%, respectively. Conclusion: Lipiodol marking is an effective way of demarcating BC. However, it is necessary to address the comorbidities of elderly patients.
- Open Access
- 1 July 2016
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 89 (1063) , 20150938
Clinical evaluation of18F-fludeoxyglucose positron emission tomography/CT using point spread function reconstruction for nodal staging of colorectal cancer
Objectives:For patients with colorectal cancer, lymph node metastasis is a very important factor for prognostic and treatment determinations. 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) is among the useful tools for detecting lymph node metastasis. Recently, a new FDG-PET/CT reconstruction technique for improving spatial resolution and signal-to-noise ratios, point-spread function (PSF), has become available. We assessed the effect of PSF reconstruction on standardized uptake values (SUVs) and its diagnostic accuracy for lymph node staging in patients with colorectal cancer.Methods:We retrospectively analysed records from colorectal cancer patients who underwent FDG-PET/CT for preoperative staging. All PET/CT examinations were reconstructed using ordered subset expectation maximization (OSEM) and OSEM+PSF. We compared sensitivities, specificities, positive predictive values (PPVs), negative predictive values (NPVs), and accuracies of conventional-PET/CT (recons...
- 1 July 2016
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 89 (1063) , 20150938
Open AccessClinical evaluation of18F-fludeoxyglucose positron emission tomography/CT using point spread function reconstruction for nodal staging of colorectal cancer
Objectives:For patients with colorectal cancer, lymph node metastasis is a very important factor for prognostic and treatment determinations. 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) is among the useful tools for detecting lymph node metastasis. Recently, a new FDG-PET/CT reconstruction technique for improving spatial resolution and signal-to-noise ratios, point-spread function (PSF), has become available. We assessed the effect of PSF reconstruction on standardized uptake values (SUVs) and its diagnostic accuracy for lymph node staging in patients with colorectal cancer.Methods:We retrospectively analysed records from colorectal cancer patients who underwent FDG-PET/CT for preoperative staging. All PET/CT examinations were reconstructed using ordered subset expectation maximization (OSEM) and OSEM+PSF. We compared sensitivities, specificities, positive predictive values (PPVs), negative predictive values (NPVs), and accuracies of conventional-PET/CT (recons...
- Open Access
- 31 January 2012
- Published by Springer Nature in Radiation Oncology
- Vol. 7 (1) , 15
Narrow safety range of intraoperative rectal irradiation exposure volume for avoiding bleeding after seed implant brachytherapy
Rectal toxicity is less common after 125I seed implant brachytherapy for prostate cancer, and intraoperative rectal dose-volume constraints (the constraint) is still undetermined in pioneering studies. As our constraint failed to prevent grade 2 or 3 rectal bleeding (bled-pts) in 5.1% of patients, we retrospectively explored another constraint for the prevention of rectal bleeding. The study population consisted of 197 patients treated with the brachytherapy as monotherapy using real-time intraoperative transrectal ultrasound (US)-guided treatment at a prescribed dose of 145 Gy. Post-implant dosimetry was performed on Day 1 and Day 30 after implantation using computed tomography (CT) imaging. Rectal bleeding toxicity was classified by CTC-AE ver. 3.0 during a mean 29-month (range, 12-48 months) period after implantation. The differences in rV100s were compared among intraoperative, Day 1 and Day 30 dosimetry, and between that of patients with grade 2 or 3 rectal bleeding (the bled-pts) and of the others (the spared-pts). All patients were divided into groups based on provisional rV100s that were increased stepwise in 0.1-cc increments from 0 to 1.0 cc. The difference in the ratios of the bled-pts to the spared-pts was tested by chi-square tests, and their odds ratios were calculated (bled-OR). All statistical analyses were performed by t-tests. The mean values of rV100us, rV100CT_1, and rV100CT_30 were 0.31 ± 0.43, 0.22 ± 0.36, and 0.59 ± 0.68 cc, respectively. These values temporarily decreased (p = 0.020) on Day 1 and increased (p = 0.000) on Day 30. There was no significant difference in rV100s between the bled-pts and spared-pts at any time of dosimetry. The maximum bled-OR was identified among patients with an rV100us value above 0.1 cc (p = 0.025; OR = 7.8; 95% CI, 1.4-145.8); an rV100CT_1 value above 0.3 cc (p = 0.014; OR = 16.2; 95% CI, 3.9-110.7), and an rV100CT_30 value above 0.5 cc (p = 0.019; OR = 6.3; 95% CI, 1.5-42.3). By retrospective analysis exploring rV100 as intraoperative rectal dose-volume thresholds in 125I seed implant brachytherapy for prostate cancer, it is proved that rV100 should be less than 0.1 cc for preventing rectal bleeding.
- 31 January 2012
- Published by Springer Nature in Radiation Oncology
- Vol. 7 (1) , 15
Open AccessNarrow safety range of intraoperative rectal irradiation exposure volume for avoiding bleeding after seed implant brachytherapy
Rectal toxicity is less common after 125I seed implant brachytherapy for prostate cancer, and intraoperative rectal dose-volume constraints (the constraint) is still undetermined in pioneering studies. As our constraint failed to prevent grade 2 or 3 rectal bleeding (bled-pts) in 5.1% of patients, we retrospectively explored another constraint for the prevention of rectal bleeding. The study population consisted of 197 patients treated with the brachytherapy as monotherapy using real-time intraoperative transrectal ultrasound (US)-guided treatment at a prescribed dose of 145 Gy. Post-implant dosimetry was performed on Day 1 and Day 30 after implantation using computed tomography (CT) imaging. Rectal bleeding toxicity was classified by CTC-AE ver. 3.0 during a mean 29-month (range, 12-48 months) period after implantation. The differences in rV100s were compared among intraoperative, Day 1 and Day 30 dosimetry, and between that of patients with grade 2 or 3 rectal bleeding (the bled-pts) and of the others (the spared-pts). All patients were divided into groups based on provisional rV100s that were increased stepwise in 0.1-cc increments from 0 to 1.0 cc. The difference in the ratios of the bled-pts to the spared-pts was tested by chi-square tests, and their odds ratios were calculated (bled-OR). All statistical analyses were performed by t-tests. The mean values of rV100us, rV100CT_1, and rV100CT_30 were 0.31 ± 0.43, 0.22 ± 0.36, and 0.59 ± 0.68 cc, respectively. These values temporarily decreased (p = 0.020) on Day 1 and increased (p = 0.000) on Day 30. There was no significant difference in rV100s between the bled-pts and spared-pts at any time of dosimetry. The maximum bled-OR was identified among patients with an rV100us value above 0.1 cc (p = 0.025; OR = 7.8; 95% CI, 1.4-145.8); an rV100CT_1 value above 0.3 cc (p = 0.014; OR = 16.2; 95% CI, 3.9-110.7), and an rV100CT_30 value above 0.5 cc (p = 0.019; OR = 6.3; 95% CI, 1.5-42.3). By retrospective analysis exploring rV100 as intraoperative rectal dose-volume thresholds in 125I seed implant brachytherapy for prostate cancer, it is proved that rV100 should be less than 0.1 cc for preventing rectal bleeding.
- 1 May 2011
- Published by Elsevier in Brachytherapy
- Vol. 10 (3) , 208-213
Effects of ellipsoid prostate deformation on dose delivery during permanent interstitial brachytherapy
- 1 May 2011
- Published by Elsevier in Brachytherapy
- Vol. 10 (3) , 208-213
Effects of ellipsoid prostate deformation on dose delivery during permanent interstitial brachytherapy
- 1 January 2010
- Published by Elsevier in Brachytherapy
- Vol. 9 (1) , 71-75
Duodenal complications in radiotherapy for bile duct cancer: A dose–volume histogram analysis
- 1 January 2010
- Published by Elsevier in Brachytherapy
- Vol. 9 (1) , 71-75
Duodenal complications in radiotherapy for bile duct cancer: A dose–volume histogram analysis
- Open Access
- 1 April 2003
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 33 (4) , 198-201
Iridium-192 Brachytherapy for Hemorrhagic Angiosarcoma of the Scalp: a Case Report
A 60-year-old woman presented with multicentric skin tumors of the head. The histologically proven hemangioendothelioma was bleeding as a result of disseminated coagulopathy. In addition to immunotherapy, 6 MeV electron beam radiotherapy was used for the purpose of hemostasis with a single portal, 20 × 20 cm in size, covering the whole scalp from the top of the head. The radiotherapy was discontinued after 39 Gy/13 fractions/20 days because of the progress in size of a peripheral tumor and the stability of coagulopathy. After another electron boost delivery by two portals focused to exophytic parietal and temporal tumors of 20 Gy/10 fractions, high dose rate brachytherapy with a surface mold technique was performed, 3 Gy/fraction, four fractions/week, for a total of 36 Gy. It induced partial regression of the tumor and complete recovery of platelet counts from 2.5 × 104 to 18.2 × 104. The tumor disappeared in 3 months. No late side effects occurred, except for permanent alopecia. The patient developed a cervical lymph node metastasis 1 year after and marginal recurrence 2 years after the initial treatment. Both recurrent tumors were successfully treated by 4 MV external photons of 60 Gy/20 fractions/46 days and electron beam irradiation of 60 Gy/20 fractions/29 days, respectively. She has remained disease free for 3 years after the initial presentation.
- 1 April 2003
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 33 (4) , 198-201
Open AccessIridium-192 Brachytherapy for Hemorrhagic Angiosarcoma of the Scalp: a Case Report
A 60-year-old woman presented with multicentric skin tumors of the head. The histologically proven hemangioendothelioma was bleeding as a result of disseminated coagulopathy. In addition to immunotherapy, 6 MeV electron beam radiotherapy was used for the purpose of hemostasis with a single portal, 20 × 20 cm in size, covering the whole scalp from the top of the head. The radiotherapy was discontinued after 39 Gy/13 fractions/20 days because of the progress in size of a peripheral tumor and the stability of coagulopathy. After another electron boost delivery by two portals focused to exophytic parietal and temporal tumors of 20 Gy/10 fractions, high dose rate brachytherapy with a surface mold technique was performed, 3 Gy/fraction, four fractions/week, for a total of 36 Gy. It induced partial regression of the tumor and complete recovery of platelet counts from 2.5 × 104 to 18.2 × 104. The tumor disappeared in 3 months. No late side effects occurred, except for permanent alopecia. The patient developed a cervical lymph node metastasis 1 year after and marginal recurrence 2 years after the initial treatment. Both recurrent tumors were successfully treated by 4 MV external photons of 60 Gy/20 fractions/46 days and electron beam irradiation of 60 Gy/20 fractions/29 days, respectively. She has remained disease free for 3 years after the initial presentation.